- Defence Therapeutics (DTC) has been granted a patent covering its breakthrough vaccine platform technology
- The patent provides broad protection for Defence’s vaccine platform
- The U.S. patent, issued by the United States Patent and Trademark Office (USPTO), demonstrates the company’s commitment to becoming a leader in vaccine development
- Defence Therapeutics is a biotechnology company
- Defence Therapeutics Inc. (DTC) opened trading at C$3.80 per share
Defence Therapeutics (DTC) has been granted a U.S. patent covering its breakthrough vaccine platform technology.
The vaccine platform utilizes components of Defence’s proprietary Accum™ technology.
The patent, issued by the United States Patent and Trademark Office (USPTO), provides broad protection for Defence’s vaccine platform that can be incorporated into virtually any cell-based or protein subunit vaccine to enhance immunogenicity.
Defence’s patent was allowed by the USPTO without any substantive amendments, which is a strong testament to the novelty and inventiveness of the pioneering technology, as well as to the robust data supporting the utility and versatility of the vaccine platform. Included in the patent are claims directed to immunogenic compositions of matter comprising Defence’s first and subsequent generation Accum™ technologies, as well as methods directed to their production and use in vaccination and/or immunotherapy.
“This US patent is not only another important milestone in protecting the commercial potential of Accum™, but along with new patent families currently in the pipeline, demonstrates Defence’s strong overall commitment to protecting the innovation and commercial potential of the entire product portfolio as well as to becoming a leader in vaccine development,” said Sébastien Plouffe, Chief Executive Officer of Defence Therapeutics Inc.
Defence Therapeutics is a biotechnology company working on engineering the next-generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics’ platform is the ACCUM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
Defence Therapeutics Inc. (DTC) opened trading at C$3.80 per share.